Testosterone enanthate auto-injector

COMBINATION_PRODUCT4 trials

Sponsors

Antares Pharma Inc.

Conditions

Hypogonadism

Phase 1

Pharmacokinetic Study of Subcutaneous Testosterone Enanthate

CompletedNCT02233751

Antares Pharma Inc.Hypogonadism

Start: 2014-09-30End: 2014-10-31Updated: 2019-04-19

Phase 2

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

CompletedNCT02777242

Antares Pharma Inc.Hypogonadism

Start: 2016-06-30End: 2016-08-31Updated: 2018-03-22

Phase 3

Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism

CompletedNCT02159469

Antares Pharma Inc.Hypogonadism

Start: 2014-07-31End: 2015-11-30Updated: 2018-02-07

Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism

CompletedNCT02504541

Antares Pharma Inc.Hypogonadism

Start: 2015-07-31End: 2016-06-30Updated: 2018-03-30

Related Papers

SAT-037 Effect of Weight on Serum Testosterone with Subcutaneous Testosterone Enanthate in Men with Testosterone Deficiency

Journal of the Endocrine Society2020-04-01

Safety of a New Subcutaneous Testosterone Enanthate Auto-Injector: Results of a 26-Week Study

The Journal of Sexual Medicine2019-09-2132 citations